Alzheimer's Drug Trial Offers Mixed Results
Preliminary results of a Phase II clinical trial of the Alzheimer's disease treatment Flurizan did not achieve "statistical significance in all of its primary endpoints," according to an Associated Press report of a statement by drug company Myriad Genetics Inc.
However, the 12-month trial of 207 patients with mild Alzheimer's did yield some encouraging news.
The company on Monday said preliminary data showed a positive trend in those patients taking 800 milligrams of Flurizan twice daily. In patients with mild forms of Alzheimer's, 41 percent showed a slowing of decline into dementia after 12 months, and 29 percent showed a slowing in cognitive decline, compared to those patients taking a placebo, the AP said.
Flurizan is a selective amyloid beta 42 lowering agent. Abeta42 is the primary component of senile plaques that accumulate in the brain of patients with Alzheimer's disease.
-----
Copyright � 2005 ScoutNews, LLC. All rights reserved.
|
